IL17A and plasma cell myeloma: In accordance with published studies [20,21,22], in the current study, patients in the WW myeloma group had increased levels of IL-17 compared to the active treatment cohort; this could be related to the increased amounts of IL-6 in the bone marrow of myeloma patients with active disease that promotes the production of T helper 17 cells from CD4 naive cells.